Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma
Authors
Keywords
-
Journal
Cancer Medicine
Volume 6, Issue 9, Pages 2164-2176
Publisher
Wiley
Online
2017-08-11
DOI
10.1002/cam4.1115
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NCCN Task Force Report: Bone Health in Cancer Care
- (2017) Julie R. Gralow et al. Journal of the National Comprehensive Cancer Network
- The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl
- (2016) Jennifer L. Dine et al. BREAST CANCER RESEARCH AND TREATMENT
- Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models
- (2016) Vasilios Liapis et al. Cancer Medicine
- Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma
- (2015) Vasilios Liapis et al. CANCER LETTERS
- Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer
- (2015) Mitesh J. Borad et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic applications of TRAIL receptor agonists in cancer and beyond
- (2015) Gustavo P. Amarante-Mendes et al. PHARMACOLOGY & THERAPEUTICS
- Targeting Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL): A Promising Therapeutic Strategy in Gliomas
- (2015) George A. Alexiou et al. Seminars in Pediatric Neurology
- Review of the Molecular Pathogenesis of Osteosarcoma
- (2014) Jin-Peng He et al. Asian Pacific Journal of Cancer Prevention
- Recent advances in osteosarcoma
- (2014) Sander M Botter et al. CURRENT OPINION IN PHARMACOLOGY
- Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma
- (2014) Sant P. Chawla et al. JOURNAL OF CLINICAL ONCOLOGY
- New molecular insights into osteosarcoma targeted therapy
- (2013) Jilong Yang et al. CURRENT OPINION IN ONCOLOGY
- Death receptor agonist therapies for cancer, which is the right TRAIL?
- (2013) Pamela M. Holland CYTOKINE & GROWTH FACTOR REVIEWS
- A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer
- (2012) H. L. Kindler et al. ANNALS OF ONCOLOGY
- Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia
- (2012) Tadeusz Robak Future Oncology
- Bone Health in Adult Cancer Survivorship
- (2012) Maryam B. Lustberg et al. JOURNAL OF CLINICAL ONCOLOGY
- An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells
- (2011) Nicholas S. Wilson et al. CANCER CELL
- Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL
- (2011) Pamela M. Holland CANCER LETTERS
- Cripto Regulates Hematopoietic Stem Cells as a Hypoxic-Niche-Related Factor through Cell Surface Receptor GRP78
- (2011) Kenichi Miharada et al. Cell Stem Cell
- Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?
- (2011) Angela Alama et al. DRUG DISCOVERY TODAY
- Imaging in bone sarcomas. The chemotherapist's point of view
- (2011) Stefano Ferrari et al. EUROPEAN JOURNAL OF RADIOLOGY
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer
- (2010) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma
- (2009) A. Labrinidis et al. CLINICAL CANCER RESEARCH
- Apomab, a fully human agonistic antibody to DR5, exhibits potent antitumor activity against primary and metastatic breast cancer
- (2009) I. Zinonos et al. MOLECULAR CANCER THERAPEUTICS
- Osteosarcoma Development and Stem Cell Differentiation
- (2008) Ni Tang et al. CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
- Ligand-Based Targeting of Apoptosis in Cancer: The Potential of Recombinant Human Apoptosis Ligand 2/Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (rhApo2L/TRAIL)
- (2008) Avi Ashkenazi et al. JOURNAL OF CLINICAL ONCOLOGY
- Potent and Highly Selective Hypoxia-Activated Achiral Phosphoramidate Mustards as Anticancer Drugs
- (2008) Jian-Xin Duan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonists
- (2008) Avi Ashkenazi NATURE REVIEWS DRUG DISCOVERY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search